Levels of Salivary Immunoglobulin A (SIgA) in HIV Infected Children

Secretory IgA is the main type of immunoglobulin in saliva and is considered to be the main secretion factor of adaptive immunity in the mouth. Objective: To assess the effect of Anti Retroviral Therapy on SIgA levels in saliva of HIV infected children. Study Design: A cross-sectional sample of 50 HIV infected children aged 6-8 years were divided into 2 groups ; Group 1: children prior to onset of anti-retroviral therapy and Group 2: children undergoing anti-retroviral therapy. Stimulated whole saliva samples were collected from each child following I hour of breakfast. The samples were placed on ice packs and immediately transferred to a laboratory, processed and total SIgA quantification was estimated using ELISA. Data obtained was statistically analyzed. Results: Among HIV infected children, significantly low SIgA levels of 6.2 mg/dl was seen in children prior to ART. Conclusion: Salivary IgA levels were significantly low in HIV infected children, particularly in children prior to ART.

ART, salivary IgA, dental caries, HIV

1. McCullough MJ, Firth NA, Reade PC. Human immunodeficiency virus infection: a review of the mode of infection, pathogenesis, disease course, and the general and clinical manifestations. Aust Dent J, 42(1):30-7, 1997.

2. dos Santos Pinheiro R, França TT, Ribeiro CM, Leão JC, de Souza IP, Castro GF. Oral manifestations in human immunodeficiency virus infected children in highly active antiretroviral therapy era. J Oral Pathol Med, 38(8):613-22, 2009.

3. Brown DM, Jabra-Rizk MA, Falkler WA Jr, Baqui AA, Meiller TF. Identification of Candida dubliniensis in a study of HIV-seropositive pediatric denal patients. Pediatr Dent, 22: 234–238, 2000.

4. Mittal M. AIDS in children--epidemiology, clinical course, oral manifestations and management. J Clin Pediatr Dent, 34(2):95-102, 2009.

5. Naidoo S, Chikte U. Oro-facial manifestations in paediatric HIV: a comparative study of institutionalized and hospital outpatients. Oral Dis, 10(1):13-8, 2004.

6. Bosco VL, Birman EG, Cury AE, Paula CR. Yeasts from the oral cavity of children with AIDS: exoenzyme production and antifungal resistance. Pesqui Odontol Bras, 3: 217-22, 2003.

7. Grando LJ, Yurgel LS, Machado DC, Silva CL, Menezes M, Picolli C. Oral manifestations, counts of CD4+ T lymphocytes and viral load in Brazilian and American HIV-infected children. Pesqui Odontological Bras, 16: 18-25, 2002.

8. Centres for Disease Control Prevention. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. 1994; MMWR 43(RR-12):1-10.

9. Magalhães MG, Bueno DF, Serra E, Gonçalves R. Oral manifestations of HIV positive children. J Clin Pediatr Dent, 25(2):103-6, 2001.

10. Greenspan JS, Greenspan D. The epidemiology of the oral lesions of HIV infection in the developed world. Oral Dis, 8 (Suppl 2):34-9, 2002.

11. Santo AE, Tagliaferro EP, Ambrosano GM, Meneghim MC, Pereira AC. Dental status of Portuguese HIV+ patients and related variables: a multivariate analysis. Oral Dis, 16(2):176-84, 2010.

12. Bodhade AS, Ganvir SM, Hazarey VK. Oral manifestations of HIV infection and their correlation with CD4 count. J Oral Sci, 53(2):203-11, 2011.

13. Castro GF, Souza IP, Lopes S, Stashenko P, Teles RP. Salivary IgA to cariogenic bacteria in HIV-positive children and its correlation with caries prevalence and levels of cariogenic microorganisms. Oral Microbiol Immunol, 19(5):281-8, 2004.

14. Rubinstein A. HIV infections in infants and children. In: Holmes KK, ed. Sexually Transmitted Diseases, 1990; 2nd edn.McGraw-Hill: New York, pp 843-899.

15. McConnell MS, Byers RH, Frederick T, Peters VB, Dominguez KL, Sukalac T, Greenberg AE, Hsu HW, Rakusan TA, Ortiz IR, Melville SK, Fowler MG. Pediatric Spectrum of HIV Disease Consortium. Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001. J Acquir Immune Defic Syndr, 38(4):488-94, 2005.

16. Challacombe SJ, Naglik JR. The effects of HIV infection on oral mucosal immunity. Adv Dent Res, 19(1):29-35, 2006.

17. Mandel ID, Barr CE, Turgeon L. Longitudinal study of parotid saliva in HIV-1 infection. J Oral Pathol Med, 21:209–213, 1992.

18. Muller F, Holberg-Petersen M, Rollag H, Degre M, Brandtzaeg P, Froland SS. Nonspecific oral immunity in individuals with HIV infection. J Acquir Immune Defic Syndr, 5:46-51, 1992.

19. Sweet SP, Rahman D, Challacombe SJ. IgA subclasses in HIV disease: dichotomy between raised levels in serum and decreased secretion rates in saliva. Immunology, 86: 556-59, 1995.

20. Atkinson JC, Yeh C, Oppenheim FG, Bermudez D, Baum BJ, Fox PC. Elevation of salivary antimicrobial proteins following HIV-1 infection. J Acquir Immune Defic Syndr, 3:41-48, 1990.

21. Grimoud AM, Arnaud C, Dellamonica P, Lodter JP. Salivary defense factor concentrations in relation to oral and general parameters in HIV positive patients. Eur J Oral Sci, 106: 979-85, 1998.

22. Gona P, Van Dyke RB, Williams PL, Dankner WM, Chernoff MC, Nachman SA, Seage GR 3rd. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA, 296(3):292-300, 2006.

23. Flint SR, Tappuni A, Leigh J, Schmidt-Westhausen AM, MacPhail L. (B3) Markers of immunodeficiency and mechanisms of HAART therapy on oral lesions. Adv Dent Res, 19(1):146-51, 2006.

24. Borg-von Zepelin M, Meyer I, Thomssen R, Würzner R, Sanglard D, Telenti A, Monod M. HIV-Protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J Invest Dermatol, 113(5):747-51, 1999.

25. Drobacheff C, Millon L, Monod M, Piarroux R, Robinet E, Laurent R, Meillet D. Increased serum and salivary immunoglobulins against Candida albicans in HIV-infected patients with oral candidiasis. Clin Chem Lab Med, 39(6):519-26, 2001.

26. Inthachark K, Pongsiriwet D , Akarathum N, Sriburee P, Iamaroon A. Oral Lesions and Dental Caries Status in Vertically HIV- Infected Children: an Epidemiological Survey at the Sanpathong Hospital, Chiang Mai. Chiang Mai Dental Journal, 30(1):10-12, 2009.

27. Schmidt-Westhausen AM, Priepke F, Bergmann FJ, Reichart PA.Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med, 29(7):336-41, 2000.

28. Cerqueira DF, Portela MB, Pomarico L, de Araújo Soares RM, de Souza IP, Castro GF. Oral Candida colonization and its relation with predisposing factors in HIV-infected children and their uninfected siblings in Brazil: the era of highly active antiretroviral therapy. J Oral Pathol Med, 39(2):188-94, 2010.

29. Domaneschi C, Massarente DB, de Freitas RS, de Sousa Marques HH, Paula CR, Migliari DA, Antunes JL. Oral colonization by Candida species in AIDS pediatric patients. Oral Dis, 17(4):393-8, 2011.

30. Nair PN, Schroeder HE. Duct-associated lymphoid tissue (DALT) of minor salivary glands and mucosal immunity. Immunology, 57(2):171- 80, 1986.

31. Malamud D. Oral diagnostic testing for detecting human immunodeficiency virus-1 antibodies: a technology whose time has come. Am J Med, 102(4A):9-14, 1997.

32. Liu Z, Otonari M, Naito S, Yasuda S, Tanaka H, Yoshioka H et al.Diurnal variation in secretory immunoglobulin A concentration. J Fac Agr Kyushu Univ, 48(1-2):167-74, 2003.

33. Kozlowski PA, Jackson S. Serum IgA subclasses and molecular forms in HIV infection: selective increases in monomer and apparent restriction of the antibody response to IgA1 antibodies mainly directed at env glycoproteins. AIDS Res Hum Retroviruses, 8:1773-80, 1992.

34. Tabak LA. A revolution in biomedical assessment: the development of salivary diagnostics. J Dent Educ, 65: 1335-39, 2001.

35. Gregory RL, Kindle JC, Hobbs LC, Filler SJ, Malmstrom HS. Function of anti-streptococcus mutans antibodies: Inhibition of virulence factors and enzyme neutralization. Oral Mirobial Immonol, 5:181-88, 1990.

36. Legler DW, McGhee JR, Lynch DP, Mesteck JF, Shaefer ME, Carson J, et al. Immunodeficiency disease and dental caries in man. Arch Oral Biol, 26:905-10, 1981.

37. Cogulu D, Sabah E, Kutukculer N, Ozkinay F. Evaluation of the relationship between caries indices and salivary secretory IgA, salivary pH, buffering capacity and flow rate in children with Down’s syndrome. Arch Oral Biol, 51:23-8, 2006.

38. Rose PT, Gregory RL, Gfell LE, Hughes CV. IgA antibodies to Streptococcus mutans in caries-resistant and -susceptible children. Pediatr Dent, 16:272-5, 1994.

39. deFarias DG, Bezerra AC. Salivary antibodies, amylase and protein from children with early childhood caries. Clin Oral Investig, 7:154-7, 2003.

40. Bruno B, Pezzini A, Menegazzi M. Salivary levels of immunoglobulin and dental caries in children. Boll Soc Ital Biol Sper, 61:381-6, 1985.

41. Coogan MM, Sweet SP, Challacombe SJ. Immunoglobulin A (IgA), IgA1, and IgA2 antibodies to Candida albicans in whole and parotid saliva in human immunodeficiency virus infection and AIDS. Infect Immun, 62:892-96, 1994. 42.

42. Subramaniam P, Kumar K. Oral mucosal status and salivary IgA levels of HIV-infected

43. children. J Oral Pathol Med, 42(9):705-10, 2013.

44. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA, 280(1):72-7, 1998.

45. Lacabaratz-Porret C, Urrutia A, Doisne JM, Goujard C, Deveau C, Dalod M, Meyer L, Rouzioux C, Delfraissy JF, Venet A, Sinet M. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J Infect Dis, 187(5):748-57, 2003.

46. Younes SA, Trautmann L, Yassine-Diab B, Kalfayan LH, Kernaleguen AE, Cameron TO, Boulassel R, Stern LJ, Routy JP, Grossman Z, Dumont AR, Sekaly RP. The duration of exposure to HIV modulatesthe breadth and the magnitude of HIV-specific memory CD4+ T cells. J Immunol, 178(2):788-97, 2007.

47. Oxenius A, Price DA, Easterbrook PJ, O’Callaghan CA, Kelleher AD, Whelan JA, Sontag G, Sewell AK, Phillips RE. Early highly active anti retro viral therapy for acute HIV1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A, 97(7):3382-7, 2000.

48. Nabbanja J, Gitta S, Peterson S, Rwenyonyi CM. Orofacial manifestations in HIV positive children attending Mildmay Clinic in Uganda. Odontology, 101(1):116-20, 2013.

49. Pomarico L, Cerqueira DF, de Araujo Soares RM, de Souza IP, de Araujo Castro GF, Socransky S, Haffajee A, Teles RP. Associations among the use of highly active antiretroviral therapy, oral candidiasis, oral Candida species and salivary immunoglobulin A in HIV-infected children. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 108(2):203-10, 2009.

50. Matsuda S, Oka S, Honda M, Takebe Y, Takemori T. Characteristics of IgA antibodies against HIV-1 in sera and saliva from HIV-seropositive individuals in different clinical stages. Scand J Immunol, 38(5):428-34, 1993.

51. Malamud D. Saliva as a diagnostic fluid. BMJ, 305(6847):207-8, 1992.

52. Ramos-Gomez FJ, Folayan MO. Oral health considerations in HIV-infected children. Curr HIV/AIDS Rep, 10(3):283-93, 2013.

53. Martinez-Sandoval B, Ceballos-Hernández H, Téllez-Rodríguez J, Xochihua-Díaz L, Durán-Ibarra G, Pozos-Guillen AJ. Idiopathic ulcers as an oral manifestation in pediatric patients with AIDS: multidisciplinary management. J Clin Pediatr Dent, 37(1):65-9, 2012.

54. de Aguiar Ribeiro A, Portela MB, de Souza IP. The oral health of HIV-infected Brazialian children. Int J Paediatr Dent, 23(5):359-65, 2013.